641 related articles for article (PubMed ID: 25404426)
1. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
Mensch A; Stock S; Stollenwerk B; Müller D
Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting.
Morais J; Aguiar C; McLeod E; Chatzitheofilou I; Fonseca Santos I; Pereira S
Rev Port Cardiol; 2014 Sep; 33(9):535-44. PubMed ID: 25241380
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.
Rattanachotphanit T; Limwattananon C; Waleekhachonloet O; Limwattananon P; Sawanyawisuth K
Pharmacoeconomics; 2019 Feb; 37(2):279-289. PubMed ID: 30387074
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
[TBL] [Abstract][Full Text] [Related]
8. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation (NVAF) in Iran.
Tajik A; Abbasi A; Goudarzi Z; Izadi-Moud A; Varmaghani M
Clin Cardiol; 2024 Jun; 47(6):e24311. PubMed ID: 38923583
[TBL] [Abstract][Full Text] [Related]
10. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
Kleintjens J; Li X; Simoens S; Thijs V; Goethals M; Rietzschel ER; Asukai Y; Saka Ö; Evers T; Faes P; Vansieleghem S; De Ruyck M
Pharmacoeconomics; 2013 Oct; 31(10):909-18. PubMed ID: 24030788
[TBL] [Abstract][Full Text] [Related]
12. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Hospodar AR; Smith KJ; Zhang Y; Hernandez I
Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
Liu CY; Chen HC
Clin Drug Investig; 2017 Mar; 37(3):285-293. PubMed ID: 27988835
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Rudakova AV; Tatarskiĭ BA
Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China.
Liu L; Hong D; Ma K; Lu X
J Clin Pharm Ther; 2021 Jun; 46(3):658-668. PubMed ID: 33226144
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
Shah A; Shewale A; Hayes CJ; Martin BC
Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]